An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer

Clinical Practice Surveillance of the Use of Herceptin in Patients With HER2-positive Advanced Adenocarcinoma of the Stomach or Gastro-esophageal Junction (GEJ) (HERMES)

This observational, multicenter study will assess the efficacy and safety of Herceptin (trastuzumab) in routine clinical practice in patients with HER2-positive advanced adenocarcinoma of the stomach or gastro-esophageal junction. Data from patients will be collected for approximately 12 months.

Inclusion Criteria:

• Adult patients, >/=18 years of age
• Histologically confirmed advanced adenocarcinoma of the stomach or gastro-esophageal junction (GEJ) with locally advanced and/or metastatic disease
• HER2-positive tumor
• Patients who are eligible for treatment with Herceptin according to the judgment of the physician

Exclusion Criteria:

• Unwilling or unable to sign informed consent form
• Any contraindications, interactions and incompatibilities to Herceptin